Piper Sandler initiated coverage of Adagio Medical Holdings (NASDAQ: ADGM) with an “overweight” rating and price target of $3.00. The stock closed at $1.33 on April 13th.
Adagio is a pre-commercial medtech company that has developed a unique technology called ultra-low temperature cryoablation (ULTC) for the treatment of ventricular tachycardia. ULTC is designed to deliver transmural lesions across thick ventricular heart tissue to improve patient outcomes for this deadly disease, while also improving the safety profile versus RF ablation. The company has completed enrollment in its FDA IDE trial, called FULCRUM-VT, and pivotal data will be presented in a Late-Breaking Session at Heart Rhythm Society (HRS) 2026 on April 26th.
Senior Research Analyst, Matt O’Brien, writes, “We estimate the current domestic market opportunity for VT ablation is $1.6B and only ~15% penetrated (due to high complication rates for traditional therapeutic options), leaving ample runway for growth.”
Piper’s $3 price target for ADGM is based on ~6.5x its 2028 sales estimate of $8 million.
“Shares of ADGM have held up comparatively well versus many smid-cap medtech names this year,” adds Mr. O’Brien. “Given our expectations that approval of ADGM’s ULTC technology will drive meaningful revenue growth, we set our target multiple at a premium to the peer median.”
